Arthrex Eclipse™ Shoulder Prosthesis

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2015 by Arthrex, Inc.
Information provided by (Responsible Party):
Arthrex, Inc. Identifier:
First received: February 11, 2013
Last updated: November 24, 2015
Last verified: November 2015
A Prospective, Randomized, Multicenter Study comparing the Safety and Effectiveness of Arthrex's Eclipse™ Shoulder to the Univers™ II Shoulder Prosthesis in patients with a degenerative joint disease.

Condition Intervention
Device: Univers™
Device: Eclipse™ Total Shoulder Replacement

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Multicenter Study Comparing the Safety and Effectiveness of Arthrex's Eclipse™ Shoulder Prothesis to the Univers™ II Shoulder Prosthesis in Patients With a Degenerative Joint Disease

Resource links provided by NLM:

Further study details as provided by Arthrex, Inc.:

Primary Outcome Measures:
  • Composite Clinical Success [ Time Frame: 2 year ] [ Designated as safety issue: No ]

    Composite of Clinical Success includes:

    1. constant score change of greater than 10
    2. Adjusted Constant Score greater than or equal to 54
    3. Radiographical Success: Patient meets acceptance criteria for humeral radiolucency, humeral migration/subsidence, glenoid radiolucency, glenoid migration/subsidence, device condition and periprosthetic fracture.

Estimated Enrollment: 350
Study Start Date: January 2013
Estimated Study Completion Date: October 2018
Estimated Primary Completion Date: April 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Univer™ II
Univers™ II Total Shoulder Replacement
Device: Univers™
Experimental: Eclipse™
Eclipse™ Total Shoulder Replacement
Device: Eclipse™ Total Shoulder Replacement

Detailed Description:
The purpose of this study is to demonstrate non-inferiority of the Arthrex Eclipse™ Shoulder Prosthesis to the Arthrex Univers™ II Shoulder Prosthesis for the treatment of degenerative joint disease in subjects who are candidates for total shoulder replacement. Non-inferiority in terms of safety and effectiveness will be measured by a 2 year composite clinical success (CCS) that requires functional improvement, radiographic success, absence of reoperations and revision, and lack of serious device-related adverse events.

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The subject is > 21 years of age
  • The subject has continued symptoms in target shoulder despite at least 6 months of other treatment modalities(e.g.: anti-inflammatory, physical therapy and steroid injections)
  • The subject has a diagnosis in the target shoulder of one or more of the following:

osteoarthritis, avascular necrosis, post-traumatic arthritis, or rheumatoid arthritis.

  • The subject presents with pain and functional impairment in the index shoulder, measured by an Adjusted Constant Score of ≤50. Note: The Adjusted Constant Score will be calculated from the raw Constant Score to establish patient eligibility.
  • The subject is willing to receive implantation of the Arthrex™ Shoulder Prosthesis or Univers™ II Shoulder Prosthesis.
  • The subject must be physically and mentally willing and able to comply with all study procedures (including follow-up visits and radiographic assessments) until the conclusion of the study.
  • The subject has been informed of the nature of the study and provided written consent as approved by the sites local Institutional Review Board or Ethic Review Board.

Exclusion Criteria:

  • The subject is likely a candidate for hemi-humeral arthroplasty (i.e.: Avascular Necrosis of the humeral head without glenoid involvement (Stages 0-3): Rotator Cuff Deficient Shoulder: Glenoid Bone deficiency/deformity that precludes glenoid replacement (Walch Type B2 or C) or Fractures of the Proximal Humerus, without Glenoid involvement.
  • The subject has immature bone as defined by the absence of cancellous bone patterning, a mature, thick cortex, and stress lines within the cancellous bone.
  • The subject has obvious defects in bone quality, such as cysts or lesions, in the humeral head of the target shoulder, as demonstrated by radiographic evaluation.
  • The subject has a target shoulder a rotator cuff that is not intact and not reconstructible.
  • The subject has Irreducible 3- and 4- part proximal humeral fractures of the target shoulder.
  • The subject has documented history of foreign-body sensitivity.
  • Subject with positive pregnancy test, or lactating, or intends to become pregnant during treatment period
  • The subject has history of Schizophrenia, Bipolar Disorder and/or Major Depressive Disorder as defined by DSM IV.
  • The subject is skeletally immature demonstrated radiographically by incomplete closure of proximal humeral epiphyses.
  • The subject is at high risk for poor healing or confounding outcomes [(i.e.: clinically significant renal, hepatic, cardiac hematologic disease or endocrine disease)]
  • The subject is on immune-stimulating or immunosuppressive agents
  • The subject has co-morbidity that reduces life expectancy < 36 month.
  • The subject seeking or receiving workman's compensation for shoulder injury,
  • The subject is > 350 lbs.
  • The subject engaged in heavy labor (e.g. repetitive lifting in the excess of more than 50 lbs.)
  • The subject has had surgery in the affected shoulder in the last 12 months (with the exception of diagnostic arthroscopy without reconstruction or repair procedures)
  • The subject is engaged in active sports participation. (e.g. weight lifting involving upper extremities or involved in contact sports)
  • The subject is taking medications known to potentially interfere with bone/soft tissue healing (e.g. steroids with the exception of topical and/or inhalers)
  • The subject is a prisoners or wards of the state
  • The subject has a history of alcohol and/or substance abuse as defined by DSM IV (Diagnostic and Statistical Manual Diploma in Social Medicine)
  • The subject has an active or chronic infection, either systemic or local.
  • The subject has pathologic fractures of the affected shoulder
  • The subject has acute trauma of the affected shoulder
  • The subject has osteoporosis defined as a bone density T score of < -2.5. (A screening Questionnaire for osteoporosis, SCORE (Simple Calculated Osteoporosis Risk Estimation) and MORES (Male Osteoporosis Risk Estimation Score), will be used to screen patients who require a DEXA (dual energy x-ray absorptiometry) bone mineral density measurement.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01790113

Contact: Melissa Hirschberg 239-216-1894

United States, Arizona
Banner Research/The CORE Institute Recruiting
Sun City, Arizona, United States, 85351
Contact: Beth Gleason, MA    623-537-5695   
Contact: Susan Mauro    623-455-7125   
Principal Investigator: Arash Araghi, DO         
Sub-Investigator: John A Brown, MD         
United States, California
Orthopedics Stanford University School of Medicine Recruiting
Redwood City, California, United States, 94305
Contact: Elizabeth Handley    650-721-7614   
Principal Investigator: John Costouros, M.D.         
United States, Florida
Shands Hospital /University of Florida Withdrawn
Gainesville, Florida, United States, 32611
United States, Illinois
Rush Orthopaedics at Rush University Medical Center Recruiting
Chicago, Illinois, United States, 60607
Contact: Jae Kim    312-432-2452   
Contact: Kavita Ahuja    312-563-2216      
Principal Investigator: Anthony Romeo, M.D.         
Sub-Investigator: Nikhil Verma, M.D.         
United States, Kentucky
Ellis and Badenhausen Orthopedics PSC Recruiting
Louisville, Kentucky, United States, 40223
Contact: Erin Gish    502-587-1236 ext 2248   
Principal Investigator: Mark Smith, M.D.         
United States, Maryland
Medstar Health Research Institute/Medstar Union Hospital Active, not recruiting
Baltimore, Maryland, United States, 21237
Peninsula Orthopaedics Associates, P.A. Recruiting
Salisbury, Maryland, United States, 21804
Contact: Trish Ireland    410-749-4154 ext 189   
Principal Investigator: Thomas A Brandon, M.D.         
United States, Minnesota
Essentia Health Duluth Recruiting
Duluth, Minnesota, United States, 55805
Contact: Robert J Shultz, RN    218-786-4126   
Contact    218-786-2230   
Principal Investigator: Jeffery Klassen, MD         
United States, New York
Excelsior Orthopedics Foundation of WNY Terminated
Amherst, New York, United States, 14226
SUNY Upstate Medical Universtiy Recruiting
East Syracuse, New York, United States, 13057
Contact: Tina Craig    315-464-8618   
Principal Investigator: Kevin Setter, M.D.         
United States, Ohio
Adena Bone & Joint Not yet recruiting
Chillicothe, Ohio, United States, 45601
Contact: Ashley Harms    740-779-7220   
Contact: Sydney Cryder   
OhioHealth Research Institute at Grant Medical Center Recruiting
Columbus, Ohio, United States, 43215
Contact: Lindsey Sikora, RN    614-566-8805   
Contact: Jennifer Mull    614-566-8195   
Principal Investigator: Nathan Long, D.O.         
United States, Pennsylvania
Blair Orthopedic Associate, Inc Recruiting
Altoona, Pennsylvania, United States, 16602
Contact: Penny S Adams    814-944-4532   
Contact: Martina Synder    814-204-1191   
Principal Investigator: Joshua Port, MD         
United States, South Carolina
Palmetto Health Orthopedics (formerly Providence Orthopedics Group, LLC_Moore Orthopedics) Active, not recruiting
Lexington, South Carolina, United States, 29072
Sponsors and Collaborators
Arthrex, Inc.
Principal Investigator: Anthony Romeo, M.D. Midwest Orthopaedics at Rush University
  More Information

No publications provided

Responsible Party: Arthrex, Inc. Identifier: NCT01790113     History of Changes
Other Study ID Numbers: Arthrex 003
Study First Received: February 11, 2013
Last Updated: November 24, 2015
Health Authority: United States: Food and Drug Administration processed this record on November 27, 2015